What is Zacks Research's Estimate for BHC FY2024 Earnings?

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Research analysts at Zacks Research lifted their FY2024 earnings estimates for Bausch Health Companies in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $3.72 for the year, up from their previous estimate of $3.60. The consensus estimate for Bausch Health Companies' current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2024 earnings at $1.12 EPS, Q1 2025 earnings at $0.85 EPS, Q2 2025 earnings at $1.00 EPS, Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.28 EPS, FY2025 earnings at $4.26 EPS, Q2 2026 earnings at $1.12 EPS, Q3 2026 earnings at $1.36 EPS and FY2026 earnings at $5.01 EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the firm posted $1.03 EPS. The business's revenue for the quarter was up 12.2% on a year-over-year basis.

Several other equities research analysts also recently issued reports on the stock. Jefferies Financial Group decreased their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, August 7th. Scotiabank cut their price objective on Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating on the stock in a research report on Friday, August 2nd. Piper Sandler lowered Bausch Health Companies from a "neutral" rating to an "underweight" rating and lowered their target price for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Truist Financial reduced their price target on Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating on the stock in a research report on Thursday, July 25th. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of "Hold" and an average price target of $7.75.

Bausch Health Companies Stock Down 1.0 %

Shares of NYSE BHC traded down $0.08 during midday trading on Friday, hitting $8.10. The stock had a trading volume of 519,941 shares, compared to its average volume of 2,854,071. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -16.96 and a beta of 0.74. The company has a fifty day moving average price of $8.34 and a 200 day moving average price of $7.10.

Insider Transactions at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the transaction, the executive vice president now owns 435,198 shares of the company's stock, valued at approximately $2,702,579.58. The trade was a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 8.12% of the company's stock.

Institutional Trading of Bausch Health Companies

Several hedge funds have recently bought and sold shares of BHC. Headlands Technologies LLC bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $35,000. MQS Management LLC bought a new position in Bausch Health Companies in the 2nd quarter valued at about $71,000. Certuity LLC acquired a new position in Bausch Health Companies during the 2nd quarter valued at about $75,000. Bfsg LLC raised its position in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company's stock worth $80,000 after buying an additional 3,643 shares in the last quarter. Finally, Kendall Capital Management acquired a new stake in shares of Bausch Health Companies in the 2nd quarter worth approximately $87,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.